Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report

Dovey, Serena; Krishnamurti, Lakshmanan; Sanfilippo, Joseph S.; Gunawardena, Sriya; Mclendon, Patricia; Campbell, Mary S.; Alway, S.M.; Efymow, Brenda; Gracia, Clarisa R.

doi:10.1007/s10815-011-9698-2

Cited by 24 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel methods in preserving fertility after HCT should hasten a revision of the current indications for HLA-ID sibling HCT, extending this therapeutic option to all children who have a sickle cell anemia genotype. Oocyte cryopreservation has been reported in a patient with sickle cell disease 24 . Cryopreservation of ovarian tissue is available as a research procedure, and this tissue might be utilized to restore endocrine and reproductive function after HCT 25 .…”

Section: Transplant Results In Children: Hla-id Sibling Hctmentioning

confidence: 99%

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Walters

Castro

Sullivan

et al. 2016

Biology of Blood and Marrow Transplantation

Self Cite

107

View full text Add to dashboard Cite

Although there are a number of published trials of human leukocyte antigen (HLA) – identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the risks of transplant-related complications that include infertility and debilitating graft-versus-host disease and long-term quality of life after successful HCT are difficult to perform without prospective trials in transplant and non-transplant cohorts. However, it is possible to assess the risk of mortality and to compare published rates of survival in individuals with sickle cell disease treated and not treated by HCT. In this brief review, projections about mortality risk based upon recent published reports are reviewed and summarized. The published data show overall survival and event-survival rates of 95% and 92%, respectively, in children treated by HLA-identical sibling HCT. The overall survival in the Center for International Blood and Marrow Transplant Research (CIBMTR) (N=412) and European Blood and Marrow Transplant (EBMT) (N=487) registries was 91% and 95%, respectively. These results provide broad support for the therapeutic value of HLA-identical sibling HCT for children with sickle cell disease and serve as the basis for a strong recommendation in favor of the option of HCT when a suitable donor is available. The experience of HLA-identical sibling HCT in adults with SCD is limited but appears similar to results in children, and these preliminary observations warrant further investigation.

show abstract

Section: Transplant Results In Children: Hla-id Sibling Hctmentioning

confidence: 99%

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Walters

Castro

Sullivan

et al. 2016

Biology of Blood and Marrow Transplantation

Self Cite

107

View full text Add to dashboard Cite

show abstract

“…22 This strategy requires around 14 days and provides around 8 mature oocytes per cycle to cryopreserve in women with cancer, varying according to the age. [22][23][24] Previous studies showed that vitrified oocytes have a comparable outcome to fresh ones. 1,25 According to guidelines, it is the first option for adult women facing gonadotoxic treatment.…”

Section: Specific Issues and Limitationsmentioning

confidence: 99%

Challenges of fertility preservation in non‐oncological diseases

Condorelli

Demeestere

2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Clinicians should provide fertility counseling to all patients receiving gonadotoxic treatment. International scientific societies have mainly focused on oncological patients, and fewer efforts have been made to apply these recommendations to women diagnosed with benign disease (eg benign hematological diseases, autoimmune diseases, and gynecological or genetic disorders). However, these indications account for 8%‐13% of the demand for fertility preservation. The risk of premature ovarian failure due to treatment, or to the disease itself, can be considered fairly high for many young women. Counseling and adequate management of these women require particular attention due to the severe health conditions that are associated with some of these diseases. In this review, we address specific issues related to providing adequate fertility counseling and management for women who have been diagnosed with the major non‐oncological indications, based on the literature and on our clinical experience.

show abstract

“…Although experience is limited, patients with SCD have success with procedures and therapies that preserve fertility. [60][61][62] Cryopreservation options have expanded and depend on stage of pubertal development. Cryopreservation of sperm in pubertal males is standard and improvement of sperm banking techniques and increased use of intracytoplasmic sperm injection may increase successful outcomes.…”

Section: Hsct and Fertility Preservationmentioning

confidence: 99%

“…Successful oocyte preservation after controlled ovarian stimulation in a 19-year-old woman with SCD has been described using a protocol to avoid hyperstimulation and incorporating anticoagulation for thrombosis prevention. 60 Although oocyte collection was successful, the patient required hospitalization for pain management postoperatively. In addition, successful pregnancies in women with SCD after ovarian tissue preservation have been reported.…”

mentioning

confidence: 99%

Reproductive issues in sickle cell disease

Smith‐Whitley

2014

Blood

View full text Add to dashboard Cite

As medical advances improve survival, reduce disease-related morbidity, and improve quality of life, reproductive issues will take higher priority in the sickle cell disease (SCD) community. A wide variety of topics are addressed in this chapter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD. Etiologies of impaired male fertility are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complications of medical therapies. Much less is known about the prevalence and etiology of infertility in women with SCD. Other reproductive issues in women included in this review are pain and the menstrual cycle, contraception, and preconception counseling. Finally, long-term therapies for SCD and their impact on fertility are presented.Transfusional iron overload and gonadal failure are addressed, followed by options for fertility preservation after stem cell transplantation. Focus is placed on hydroxyurea therapy given its benefits and increasing use in SCD. The impact of this agent on spermatogenesis, azoospermia, and the developing fetus is discussed. (Blood. 2014;124(24):3538-3543) IntroductionReproductive issues in women and men with sickle cell disease (SCD) include a wide array of complications that are relatively common; however, data from well-designed, large clinical studies are limited. Many studies are quite old, but remain relevant because they describe clinical complications and problems that persist in the SCD population today despite advances in medical therapy. Not unexpectedly, some of the reproductive issues in SCD arise due to chronic medical therapies that are used increasingly to prevent or manage SCD-related morbidity. Fertility in menInfertility in men with SCD has been studied more frequently than infertility in women and appears to have multiple causes, including hypogonadism, sperm abnormalities, and erectile dysfunction (ED) due to priapism. Although a delay in sexual maturation of 1.5-2 years, on average, occurs in adolescents and young adults with SCD, 1,2 most go on to have normal sexual maturation. However, up to 24% of men with SCD may develop hypogonadism, a clinical syndrome associated with poor testosterone production, infertility, ED, and poor libido.3 Clinical characteristics include sparse facial, pubic, and axillary hair and small testicular size. Clinical laboratory findings are low testosterone levels with variable follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels. 4 Possible underlying pathophysiologic mechanisms of hypogonadism include disruptions in the hypothalamic-pituitary-gonadal axis leading to primary testicular failure. However, studies are inconsistent as to whether primary testicular failure 5,6 or secondary hypothalamic-pituitary dysfunction 3,4,[7][8][9] is the cause. A recent report found low serum testosterone levels in 8 of 34 men with SCD and all 8 had low FSH and LH levels, suggesting a central mechanism.3 Multiple theories as to why these abnormalities develop in ma...

show abstract

Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report

Cited by 24 publications

References 34 publications

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Challenges of fertility preservation in non‐oncological diseases

Reproductive issues in sickle cell disease

Contact Info

Product

Resources

About